Kehua Biotech (002022.SZ) released its results for the first half of the year, with net profit of RMB 21.1881 million, a decrease of 54.50%

Zhitong Finance ·  08/16/2023 18:32

According to the Zhitong Finance App, Kehua Biotech (002022.SZ) released its 2023 semi-annual report. During the reporting period, the company achieved operating income of 1,396 billion yuan, an increase of 54.66% over the previous year. Net profit attributable to shareholders of listed companies was RMB 21,1281 million, a year-on-year decrease of 54.50%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was achieved at 6.8851 million yuan, a year-on-year decrease of 84.63%. The basic earnings per share were $0.0411.

The report shows that the reason for the increase in operating income: according to data for the same period last year, Tianlong Company was not included in the scope of the merger; main revenue and gross margin declined due to factors such as changes in the market environment, increased industry competition, and implementation of collection policies.

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment